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Despite several review papers and experimental studies concerning the impact of chronic helminth infec-
tion on tuberculosis in recent years, there is a scarcity of data from clinical ﬁeld studies in highly endemic
areas for these diseases. We believe this is the ﬁrst randomised clinical trial investigating the impact of
albendazole treatment on the clinical and immunological outcomes of helminth co-infected tuberculosis
patients. A randomised, double-blind, placebo-controlled trial of albendazole (400 mg per day for 3 days)
in helminth-positive tuberculosis patients was conducted in Gondar, Ethiopia. The primary outcome was
clinical improvement (DTB score) after 2 months. Among secondary outcomes were changes in the levels
of eosinophils, CD4+ T cells, regulatory T cells, IFN-c, IL-5 and IL-10 after 3 months. A total of 140 hel-
minth co-infected tuberculosis patients were included with an HIV co-infection rate of 22.8%. There
was no signiﬁcant effect on the primary outcome (DTB score: 5.6 ± 2.9 for albendazole versus 5.9 ± 2.5
for placebo, P = 0.59). The albendazole-treated group showed a decline in eosinophil cells (P = 0.001)
and IL-10 (P = 0.017) after 3 months. In an exploratory analysis after 12 weeks, the albendazole treated
group showed a trend towards weight gain compared with the placebo group (11.2 ± 8.5 kg versus
8.2 ± 8.7 kg, P = 0.08)). The reductions in eosinophil counts and IL-10 show that asymptomatic helminth
infection signiﬁcantly affects host immunity during tuberculosis and can be effectively reversed by
albendazole treatment. The clinical effects of helminth infection on chronic infectious diseases such as
tuberculosis merit further characterisation.
 2014 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
Similar to tuberculosis (TB), it has been estimated that one-
third of the global human population is infected with intestinal
parasites (World Health Organization (WHO), 2012; Salgame
et al., 2013). Several studies, including some from Ethiopia, have
shown an increased rate of helminth infection in TB patients com-
pared with household contacts living in the same room with activeTB patients and the healthy population (Tristão-Sá et al., 2002;
Abate et al., 2012). The impact of helminth infection on the risk
of developing TB and during the course of active TB is not well
understood but is believed to involve helminth-induced effects
on cell mediated immunity (Bentwich et al., 1999; Borkow et al.,
2001; Elias et al., 2006).
Protective immunity in TB has been shown to be dependent on
T-helper 1 (Th1) CD4+ T cells producing IFN-c and TNF-a, as well
as cytolytic T cells (CTLs) producing granule-associated cytolytic
effector molecules (Brighenti and Andersson, 2012). It has been
postulated that helminth co-infection could modulate the protec-
tive Th1-response against TB through an effect on the Th1/Th2
balance, with increased Th2 dominance and activity of regulatory
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Th2 and Treg responses induce the production of cytokines includ-
ing IL-4 and IL-10 which are potent inhibitors of the Th1 response
(Rook, 2007; Redford et al., 2011). Indeed, in both humans and
mice there is a marked increase in Th2-related cytokines such as
IL-4, IL-5 and IL-13 following helminth infection (Anthony et al.,
2007). In human volunteers, hookworm infection is associated
with strong local and systemic Th2 and Treg responses (Gaze
et al., 2012). The vaccine currently used against TB, Bacillus Cal-
mette Guerin (BCG), is not effective against adult pulmonary TB
in sub-Saharan Africa (Tameris et al., 2013). One reason could be
that helminth infection modulates the immune response by skew-
ing the Th1/Th2 balance and thereby attenuating the effects of the
BCG vaccine (Elias et al., 2008). Several experimental studies con-
ﬁrm the immunomodulatory effect of helminths during TB
(Bentwich et al., 1999; Borkow et al., 2001; Elias et al., 2005;
Potian et al., 2011; Salgame et al., 2013). One of these studies
clearly showed that Nippostrongylus brasiliensis infection was asso-
ciated with impaired killing of Mycobacterium tuberculosis (Mtb),
an effect primarily mediated by a switch to alternatively activated
macrophages (AAMs) by IL-4 (Potian et al., 2011).
Among the very limited human studies on the interaction
between helminths and active TB, one study showed lower IFN-c
and enhanced IL-10 responses (Resende Co et al., 2007). In our
recent study from Ethiopia we found that asymptomatic helminth
infection in TB patients showed effects on host immunity in terms
of increased IgE and eosinophil levels (Abate et al., 2012). However,
clinical studies investigating the impact of deworming during
active TB in humans remains very limited. Thus, our aim was to
investigate the clinical and immunological impacts of helminth
infection in a randomised clinical trial.2. Materials and methods
2.1. Study participants
Following written informed consent, newly diagnosed patients
with pulmonary TB presenting consecutively from 1 March 2009
to 15 October 2012 at the Directly Observed Treatment Short-
Course (DOTS) Clinics of the Teaching and Referral Hospital of the
University of Gondar, the Gondar Health Centre and at Debark
Hospital, Ethiopia were eligible for enrolment. After enrollment,
helminth co-infected TB patients were randomly allocated, after
2 weeks of anti-TB treatment, to albendazole treatment (400 mg/
day for three consecutive days) or identical placebo tablets. All
helminth-positive TB patients, including the placebo group,
received anti-helminth treatment at week 12 when the follow-up
was completed. The TB treatment consisted of isoniazid, rifampicin,
ethambutol and pyrazinamide for the ﬁrst 2 months followed by
4 months of isoniazid and rifampicin. The inclusion criteria were
that patients were 15–60 years old, with a positive smear result
for acid-fast bacilli (AFB; smear-positive TB) or with clinical and
chest X-ray (CXR) results suggestive of pulmonary TB (smear-
negative TB) according to the WHO-based national guidelines
(WHO, 2012). The exclusion criteria were that patients required
hospital admission, were pregnant, infected with Schistosoma
spp., displayed symptoms of active helminth infection such as diar-
rhoea or stomach cramps, or clinical signs or medical treatment
indicating any concomitant chronic or infectious disease other than
TB/HIV.
The study received ethical clearance from the Ethics Review
Board of the University of Gondar, Ethiopia and from the Medical
Ethics Board at Linköping University, Sweden. In addition, approval
was obtained from the federal Drug Administrative and Control
Authority (DACA), Ethiopia. The data collection and patientfollow-up were monitored by an independent data and safety
monitoring board (DSMB).
2.2. Study outcome
The primary outcome was a TB score change (DTB score) at
week 8 compared with baseline. The secondary outcomes were
sputum smear conversion after 2 months, changes in the CXR
pattern from baseline to week 12, CD4+ T cell counts, IgE and
eosinophil responses, as well as changes in the frequency of Tregs
and IFN-c, IL-5 and IL-10 producing peripheral blood mononuclear
cells (PBMCs) after 3 months.
2.3. Randomization
Random numbers were generated in a block size of eight by the
Addis Continental Institute of Public Health, Ethiopia. The treat-
ment allocated for each patient was concealed in an individual
envelope. Albendazole and placebo tablets were produced by the
Addis pharmaceutical company, Ethiopia which is accredited for
Good Clinical Practice (GCP). All tablets looked identical and were
assigned a treatment code by the manufacturer. Both the investiga-
tors and clinic staff were blinded to the treatment given. The treat-
ment code was kept in a sealed envelope at the manufacturer and
opened after the last patient had been to a follow-up visit and the
data had been analysed.
2.4. Clinical and laboratory analyses
2.4.1. Socio-demographic characteristics and assessment of the TB
score
A structured questionnaire was used to collect socio-
demographic and clinical information. As previously described
(Wejse et al., 2008; Janols et al., 2012), a clinical score (TB score)
which ranges from 0 to 13 points was assessed at baseline and
2 months after anti-TB treatment. The score is composed of signs
and symptoms of TB each contributing one point (cough, haemopt-
ysis, chest pain, dyspnoea, night sweating, anaemic conjunctivae,
lung auscultation ﬁnding, tachycardia (P100/min), temperature
(P37 C), body mass index (BMI) 618 kg/m2, BMI 616 kg/m2,
mid-upper arm circumference (MUAC) 6220 mm, and MUAC
6200 mm). As previously described (Wejse et al., 2008), the TB
score was divided into three severity classes (SC-I-III) at baseline
where SC-I was 0–5 points, SC II 6–7 points and SC-III 8–13 points.
2.4.2. CXR evaluation
Grading of CXR ﬁndings of pulmonary TB was done according to
the National Tuberculosis Association of the USA as normal,
minimal, moderately advanced and far advanced TB (American
Thoracic Society, 1961). For statistical evaluation, this grading
was translated to a semi-quantitative scale, 0 (normal), 1 (mild),
2 (moderate) and 3 (far advanced TB). During follow-up at
3 months, the initial CXR was used for comparison and the radio-
logical response was classiﬁed according to a semi-quantitative
scale, (1: normalised, 2: regression, 3: no change, 4: progress).
The CXRs were read by the same senior radiologist and reading
was blinded for HIV status and treatment assignment.
2.4.3. HIV screening and determination of CD4+ T cell count
Testing for HIVwas done at the voluntary counseling and testing
clinics, and at the DOTS clinic as part of the clinical routinewith HIV
rapid test kits (Shanghai Kehua Bio-engineering Co., Ltd. (KHB HIV
1/2 rapid test strip) China), Stat-Pak (HIV 1/2, Chembio Diagnostics
Inc., USA) and Unigold (Trinity Biotech, USA). HIV-positive patients
were referred to the HIV clinics for further assessment and free anti-
retroviral treatment (ART) according to the Ethiopian HIV/AIDS
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Prevention and Control Ofﬁce, Drug Administration and Control
Authority, 2003). The ART consisted of a combination of nucleoside
and non-nucleoside reverse transcriptase inhibitors (NRTI and
NNRTI), according to the national Ethiopian HIV guideline. The
CD4+ T cell count was analysed using FACSCount (Becton Dickinson,
San Jose, California, USA).
2.4.4. Determination of IgE and eosinophil counts
Serum IgE was determined with a commercial ELISA kit
(Immundiagnostik, Germany) according to the manufacturer’s
instructions. The absolute eosinophil count of peripheral blood
was computed in cells/mm3 from the value of total and differential
white blood cell counts obtained using Cell Dyn 1800 (Abbot, USA).
2.4.5. Stool examinations
Stool samples were collected on three consecutive days from
each participant and examined using direct microscopy and
Kato-Katz techniques (Sleigh et al., 1982) by the same technician
throughout the study. The classiﬁcation into helminth-positive or
-negative was based on the examination of all three samples
together from each patient. One in 10 slides were randomly
selected and checked again by a second microscopist for quality
control. The same stool sample collection and examination strat-
egy was used at week 12.
2.4.6. Sputum smear examinations
AFB staining and examination were done on morning sputum
samples at baseline and week 8 for three consecutive days. Sputum
conversion was deﬁned as three consecutive sputum smears
becoming negative for AFB at week 8.
2.4.7. Isolation of PBMCs from whole blood
PBMCs were isolated by the density gradient separation method
using lymphoprep solution as described previously (Lyke et al.,
2005) and stored at 80 C in FCS containing 10% DMSO. Trypan-
blue exclusion dye (Sigma–Aldrich, USA) was used for detection
of cell viability and only cells from patients with viability above
75% were used for experimental assays.
2.4.8. Analysis of Tregs
PBMCs were stained with ﬂuorochrome-labeled monoclonal
mouse anti-human antibodies CD4-FITC (BD Biosciences), CD25-
Percp Cy5.5 (BDBiosciences), and CD127-Alexa 647 (BDBiosciences),
followed by ﬁxation/permeabilisation using cytoﬁx/cytoperm solu-
tion (BDBiosciences) and intracellular stainingwithmonoclonal anti-
bodies (mAbs) against Foxp3 phycoerythrin (PE) (BD Biosciences).
Cells were gated ﬁrst, based on forward and side scatter, to exclude
dead cells and cell debris. Fluorescence Minus One (FMO) controls
were used for gating purposes. Tregs were deﬁned as the population
of cells that were CD4+/CD25hi/CD127low/FOXP3+. Flow cytometry
data were collected on a FACSCalibur (BD Biosciences) using Cell-
Quest acquisition software and were then analysed using Flowjo
7.6.5 (Tree Star).
2.4.9. Analysis of IFN-c, IL-5 and IL-10 by ELISPOT
PBMCs (250,000/well) were plated onto ester-cellulose-
bottomed plates (PVDF plates, Mabtech, Sweden) coated with a
capture mAb speciﬁc for human IFN-c (1-D1K), IL-5 (TRFK5) and
IL-10 (9D7) at 15 lg/ml in PBS. Cells were incubated in a humidiﬁed
incubator at 37 C in 5% CO2 for 24 h with puriﬁed protein derivate
(PPD) antigens obtained from Mtb in duplicate using unstimulated
and anti-CD3-stimulated cells as negative and positive controls,
respectively. Spots were developed following the manufacturer’s
instructions (Marin et al., 2010).2.5. Statistical analysis
Analysis was by intention to treat. Continuous data are
expressed as means with S.D. Effects of deworming compared with
placebo on primary and secondary outcomes were evaluated by
chi-square test or Fisher´s exact test for discrete variables and
Student’s t-test for continuous variables using STATISTICA software
(Tulsa, USA). The percentage of relative change (PRC) (before and
after deworming) was calculated as follows: PRC = [(X2  X1)/
X1]  100 (Borkow and Bentwich, 2004). Multiple regression analy-
sis was performed for primary and secondary outcome variables
with a P value <0.1 in a univariate analysis including age, sex and
HIV in the model. P < 0.05 was regarded as statistically signiﬁcant.
In our previous study (Janols et al., 2012), newly diagnosed TB
patients showed a 75% decline from their baseline TB score after
2 months of anti-TB treatment only. As no previous study on the
effect of deworming on the clinical outcome had been conducted,
the total sample size without considering sub-group analyses
was a crude estimation calculated under the assumption that 210
helminth-positive TB patients would have to be included, giving
80% power at the 5% signiﬁcance level, to detect a difference in
treatment response of 15% including a 5% drop-out rate.3. Results
3.1. Study population
A total of 1251 newly diagnosed pulmonary TB patients were
screened for eligibility and of those, 846 TB patients were excluded
(Fig. 1). Of the remaining 405 eligible TB patients, 265 were
helminth-negative and were excluded from participation in the
randomised trial. A total of 140 helminth-positive TB patients were
randomly allocated to albendazole (n = 72) or placebo (n = 68)
treatments. No adverse reaction or adverse event was reported
due to albendazole treatment.3.2. Baseline characteristics
The rate of HIV co-infection was 22.8% (32/140). No signiﬁcant
difference in HIV co-infection rate was observed between the
albendazole (25%) and the placebo (21%) groups (Table 1). From
the total HIV-positive TB patients assigned to the albendazole
group, 94% were on ART while all HIV-positive TB patients in the
placebo group were on ART. There were no signiﬁcant baseline
differences between the albendazole and the placebo groups in
the proportion of patients in the three severity classes of the TB
score where 63% versus 52% were in SC-1 (P = 0.19), 19% versus
29% were in SC-II (P = 0.17) and 18% versus 19% were in SC-III
(P = 0.87) without any sub-group differences with regard to HIV.
Furthermore, no differences were detected in the baseline TB score
between the albendazole and placebo groups, including after
sub-grouping for HIV (7.8 ± 2.5 versus 7.5 ± 2.7 points, P = 0.53
for HIV-negative and 8.8 ± 2.4 versus 8.7 ± 2.2 points, P = 0.93 for
HIV-positive patients in the albendazole and placebo groups,
respectively). At week 2, this pattern was stable (3.2 ± 1.9 versus
3.3 ± 1.9, P = 0.69) in the albendazole and placebo groups, respec-
tively, without any differences with regard to HIV status.
At baseline, a signiﬁcantly lower CD4+ T cell count in the alben-
dazole group compared with placebo (489 ± 227 cells/mm3 versus
642 ± 328 cells/mm3; P = 0.025, Table 1) was found mainly in the
HIV-negative patients whereas no such baseline difference was
detected between the treatment groups among HIV-infected
patients (168 ± 119 cells/mm3 versus 190 ± 129; P = 0.62). Ascaris
lumbricoides was the most common helminth species at a preva-
lence of 52% in TB patients. There were no signiﬁcant differences
Fig. 1. Flow chart of the enrolment process for tuberculosis patients in the study trial conducted at three Directly Observed Treatment Short-Course Clinics at the Gondar
University Teaching Hospital, Debark Hospital and Gondar Health Centre, Ethiopia.
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following sub-grouping for HIV.
3.3. Effects of albendazole treatment on primary and secondary
outcomes in helminth-positive TB patients
Following deworming, there was a signiﬁcant decrease in
helminth infection in the albendazole treated group compared with
placebo at week 12 (8% versus 39%, P < 0.001). Among the 8% (4/49)
of patients in the albendazole group who remained helminth-
positive, two patients had Ascaris, one had Trichuris and one had
Strongyloides. No signiﬁcant effect of albendazole treatment on the
primary outcome (TB score change fromweek0 toweek8)was found
between the albendazole and placebo groups (5.6 ± 2.87 points,
n = 58 versus 5.9 ± 2.5; n = 61, P = 0.59, Table 2). A pronounced
decrease in eosinophil cells was observed at week 12 in albendazole
treated TB patients compared with the placebo group (D Eosinophil
cells: 379 ± 434 cells/mm3, n = 52 versus 112 ± 411 cells/mm3,
n = 51, P = 0.001, Fig. 2). No differences were detected for other sec-
ondary outcomes (changes in CXR, smear conversion rate and IgE
level) (Table 2). A non-signiﬁcant increase in the absolute mean
change of CD4+ T cells from baseline to 3 months was observed in
patients given albendazole (absolute increase: +107 CD4+ T cells/
mm3 versus +42 CD4+ T cells/mm3 in the placebo group; P = 0.16)
(Table 3). This effect was present primarily in HIV-negative albenda-
zole treated patients comparedwith the placebo group (+122 CD4+ T
cells/mm3 versus +42 CD4+ T cells/mm3; P = 0.17).
3.4. Subgroup and exploratory analyses of the effects of albendazole
treatment on TB patients
No signiﬁcant difference was observed in the mortality rate at
6 months between the albendazole and placebo groups (5.9%versus 6.3%, P = 0.91). Furthermore, no signiﬁcant differences were
observed in the primary or secondary outcomes in a sub-group
analysis of patients who had Ascaris infection at baseline (data
not shown). With regard to the inﬂuence of HIV co-infection, a sep-
arate sub-group analysis of HIV-negative and HIV-positive patients
did not reveal marked effects on primary and secondary outcomes
other than the reduction in helminth load and eosinophil counts
following albendazole treatment compared with placebo. As a sep-
arate analysis, the PRC after 12 weeks from baseline, for changes in
eosinophil and CD4+ T cell levels and weight gain, was analysed as
previously described (Borkow and Bentwich, 2004). This analysis
showed that CD4+ T cell counts increased by 422 ± 2472%, n = 44
compared with placebo 32 ± 86%, n = 36, P = 0.34 and that eosino-
phil levels decreased in the albendazole group compared with pla-
cebo (42 ± 70%, n = 52 versus 40 ± 330%, n = 51, P = 0.08). As an
exploratory ﬁnding, TB patients treated with albendazole showed
a trend towards a signiﬁcant level of weight gain compared with
the placebo group from week 0 to week 12 (11.2 ± 8.5 versus
8.2 ± 8.7 kg, P = 0.08) (Fig. 2).3.5. Effects of immunological responses following albendazole
treatment in helminth-positive TB patients compared with placebo
For assessment of immunological responses after 12 weeks
(Tregs, IFN-c, IL-5 and IL-10), a subset of 32 TB patients from the
randomised cohort were analysed. The HIV co-infection rate for
this subset was 50% (6/12) and 15% (3/20), for the albendazole
and placebo groups, respectively (P = 0.04). In a multivariate anal-
ysis at week 12 after albendazole treatment, following adjustment
for baseline IL-10 value, age, sex and HIV status, a signiﬁcant
decline in the level of IL-10 spot forming units (SFU) of PBMCs
was observed in the albendazole group compared with placebo
at week 12 (125 ± 190 versus 204 ± 168, P = 0.017). There were
Table 1
Baseline characteristics of randomised helminth-positive tuberculosis patients.
Albendazole treated n = 72 Placebo n = 68 P
Mean S.D. n Mean S.D. n
Age (years) 30.7 12.7 72 31 12.6 68 NS
Females (%) 65 72 57 68 NS
HIV-positive (%) 25 72 21 68 NS
CD4+ cells/mm3 406 248 70 551 349 65 0.006
TB score (points) 8.03 2.5 72 7.75 2.7 68 0.53
Sputum SP (%) 68 64 NS
IgE (IU/L) 955 1456 65 771 1479 58 NS
Eosinophil, (cells/mm3) 580 565 64 517 480 64 NS
CXR 42 34
Normal (%) 7 6 NS
Mild (%) 21 21 NS
Moderate (%) 29 41 NS
Far advanced (%) 43 32 NS
Ascaris lumbricoides (%) 53 72 52 68 NS
Hookworm (%) 17 72 21 68 NS
Strongyloides stercoralis (%) 15 72 13 68 NS
Trichuris trichiura (%) 10 72 12 68 NS
Hymenolepis nana (%) 3 72 2 68 NS
Taenia spp. (%) 3 72 4 68 NS
Tregs (%/CD4) 2.47 1.65 7 2.14 1.52 18 NS
IFN-c Unst (SFU) 92 86 15 85 70 22 NS
IFN-c PPD (SFU) 214 131 15 210 101 22 NS
IL-5 Unst (SFU) 75 53 15 51 47 22 NS
IL-5 PPD (SFU) 134 104 15 145 93 22 NS
IL-10 Unst (SFU) 130 155 15 146 176 22 NS
IL-10 PPD (SFU) 181 195 15 195 178 22 NS
SP, sputum positive; CXR, chest X-ray; Tregs, regulatory T cells; Unst, unstimulated; PPD, puriﬁed protein derivative-stimulated; SFU, spot forming units/250,000 peripheral
blood mononuclear cells; NS, not signiﬁcant.
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responses between albendazole and placebo groups at week 12
(Fig. 3). A separate analysis of the immunological variables for
the HIV-negative TB patients in the two groups did not show any
signiﬁcant differences.4. Discussion
To our knowledge, the present study is the ﬁrst randomised
clinical trial investigating the impact of deworming on the clinical
outcome of TB patients with active infection and simultaneously
evaluating the immunological responses during helminth-TB co-
infection. Although we found no effect on clinical improvement
measured as the change in TB score after 8 weeks, the results
clearly show that asymptomatic helminth infection during active
TB signiﬁcantly affects host immunity, as the levels of eosinophilsTable 2
Effect of deworming on helminth-positive patients with active tuberculosis.
Mean ± S.D. Albendazole Placebo Pa
Total n Total n
Primary outcome
DTB-score (W0-W8) 5.6 ± 2.87 58 5.9 ± 2.54 61 0.5
Secondary outcomes
Smear conversion W8 (%) 87 54 93 55 0.5
Changes in CXR (W0-W12) 27 22
Normal (%) 3.6 4.3 NS
Regression (%) 92.8 91.3 NS
Stable disease (%) 3.6 4.4 NS
Progression (%) 0 0 NS
DIgE KU/L (W0–W12) 181 ± 631 39 151 ± 608 41 NS
DEosinophil (W0–W12) 379 ± 434 52 112 ± 411 51 0.001
Helminth positive (%, (n)) 8 (4) 49 39 (18) 46 0.001
D, Delta change; W, week; CXR, chest X-ray; NS, not signiﬁcant.
a P value between helminth-positive tuberculosis patients in albendazole and
placebo groups.and IL-10 declined following albendazole treatment compared
with the placebo group. Additionally, in the exploratory analysis
there was a trend towards weight gain following deworming.
It has previously been shown that elevated IL-10 levels are asso-
ciated with susceptibility to TB and mice lacking IL-10 were shown
to clear BCG infection more efﬁciently (Turner et al., 2008). Mice
over-expressing IL-10 were more susceptible to Mtb infection and
had decreased numbers of activated T cells in the peripheral blood
and lung tissues (Murray, 1999). IL-10 is primarily produced by
Tregs and AAMs and it has been shown that Tregs are up-regulated
during helminth infection (Resende Co et al., 2007). In a recent
experimental study of helminth infection, AAMs had a decreased
ability to control growth of Mtb (Potian et al., 2011) and AAMs
are abundant during helminth co-infection in humans (Babu
et al., 2009). Thus, one plausible explanation for the decrease in
IL-10 observed in the current study is an effect of deworming on
the levels and responses of Tregs and AAMs. In support of our ﬁnd-
ings for the decrease in IL-10, a clinical trial on the effect of alben-
dazole in HIV patients without TB also found a reduction in IL-10 in
plasma compared with placebo (Blish et al., 2010). Thus, the ele-
vated IL-10 cytokine levels in TB-helminth co-infected patients,
together with a signiﬁcant decline during albendazole treatment,
supports the immunomodulatory effect of helminth infection, and
treatment with albendazole might improve cell mediated immune
responses against intracellular infections such as TB.
A highly signiﬁcant decline in peripheral eosinophil counts from
baseline was observed in patients treated with albendazole com-
pared with the placebo group. Although it is clear that there is a
Th2-linked increase in eosinophils induced by IL-5 following hel-
minth infection, the relative importance of eosinophils in the host
resistance against human helminth infection is unclear (Anthony
et al., 2007). Eosinophil inﬁltration to local sites of helminth infec-
tion has been shown in humans harbouring intestinal helminths
such as Trichuris trichiura (Kaur et al., 2002). The reduction in
eosinophils following albendazole treatment of helminth infection
has been previously observed in several studies (Maxwell et al.,
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Fig. 2. Participants were randomly assigned to groups and treated with either albendazole or a placebo (400 mg per day for 3 days) at baseline and followed for 12 weeks. The
graphs show the delta changes (D) of (A) tuberculosis score, P = 0.5, (B) eosinophils, P = 0.001 and (C) weight gain, P = 0.08, between two measurements before (week (W) 0)
and after deworming (W12). Each bar represents the percentage of relative change (mean ± S.E.M.) for each group. ⁄Indicates the level of signiﬁcance.
Table 3
Effect of deworming on immunological markers in helminth-positive patients with active tuberculosis. Data are presented as mean ± S.D. for week 12 levels of lymphocyte
subsets and cytokines analysed by Enzyme-Linked ImmunoSpot.
Albendazole Placebo Pa Pb
Total HIV+ n HIV- n Total HIV+ n HIV- n
CD4+ cells 522 ± 273 232 ± 188 12 627 ± 219 33 565 ± 261 219 ± 113 8 657 ± 204 30 0.57 0.46
DCD4+ cells 107 ± 214 42 ± 187 0.15
Tregs % 1.97 ± 1.59 2.6 ± 1.32 5 1.53 ± 1.71 7 1.89 ± 1.53 0.76 ± 0.43 2 2.04 ± 1.57 15 0.5 0.88
IFN-c Unst 83 ± 76 73 ± 54 6 92 ± 98 6 81 ± 74 88 ± 81 3 80 ± 75 17 0.79 0.94
IFN-c PPD 209 ± 118 201 ± 105 6 216 ± 139 6 181 ± 112 127 ± 64 3 190 ± 117 17 0.69 0.51
IL-5 Unst 59 ± 41 72 ± 39 6 47 ± 43 6 49 ± 34 40 ± 14 3 51 ± 37 17 0.8 0.47
IL-5 PPD 166 ± 97 190 ± 99 6 142 ± 98 6 175 ± 92 151 ± 57 3 179 ± 97 17 0.5 0.8
IL-10 Unst 33 ± 42 55 ± 53 6 12 ± 7 6 61 ± 77 30 ± 42 3 67 ± 81 17 0.11c 0.25
IL-10 PPD 125 ± 190 129 ± 142 6 121 ± 243 6 204 ± 168 193 ± 174 3 206 ± 172 17 0.45 0.23
D, Delta change; Tregs, regulatory T cells; Unst, unstimulated; PPD, puriﬁed protein derivative-stimulated.
a HIV-negative tuberculosis patients in the albendazole group compared with the placebo group (Student’s t-test).
b Total tuberculosis patients in the albendazole group compared with the placebo group (Student’s t-test).
c P = 0.017 in a multiple regression model including age, sex and HIV status.
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atic infection. We previously reported a signiﬁcant correlation
between eosinophilia and asymptomatic helminth infection in TB
patients (Abate et al., 2012). Thus, the observed reduction in eosin-
ophils could be regarded as an indirect measurement of reduced
worm load and Th2 response. Taken together, the reduction in
eosinophils and IL-10 strongly suggests that asymptomatic hel-
minth infection during TB induces a Th2 type immune response
which could be reversed by albendazole.
We chose TB score as a primary outcome for evaluation of clin-
ical improvement. The TB score is composed of clinical signs and
symptoms and has been used previously in clinical trials (Wejse
et al., 2009). Analysis of the change in TB score did not show anystatistical effect of deworming on the clinical outcome for TB
patients. One reason might be that the effect of the TB treatment
has a much greater impact on the TB score than the effect of
deworming as the TB score was already greatly reduced at week
2 when the albendazole was introduced. Thus, even though this
clinical scoring system was validated in highly endemic TB areas
(Wejse et al., 2008; Janols et al., 2012) for patient monitoring in
clinical studies, the TB score might not be sensitive enough to
detect subtle clinical changes such as those caused by helminth
infection. A clear limitation in that regard is also that the ﬁnal sam-
ple size for the study was not reached and that the effects of
deworming during TB infection, including sub-grouping for HIV
status, could be masked by the major clinical signs of TB and HIV.
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Fig. 3. Following random assignment to groups, helminth co-infected tuberculosis patients received albendazole or a placebo (400 mg per day for 3 days) and were assessed
for changes (week (W)12-W0) in the level of puriﬁed protein derivative-stimulated (A) IFN-c SFU, (B) IL-5 SFU, (C) IL-10 SFU and (D) percentage of regulatory T cells (Tregs) at
W0 and 12 weeks after albendazole (n = 11) or placebo treatment (n = 16) of tuberculosis patients co-infected with helminths. No signiﬁcant changes were observed except
for a signiﬁcant decrease (⁄) in IL-10 when correcting for age, sex and HIV in a multivariate regression analysis (P = 0.017). The error bars show mean ± S.E.M. (SFU, spot
forming unit/250,000 peripheral blood mononuclear cells).
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observed in secondary outcome measurements including changes
in the immunological response after month 3 in Tregs, IFN-c and
IL-5 levels (Fig. 3). This is consistent with a previous study evalu-
ating the effect of deworming in HIV patients which did not show
any signiﬁcant changes in plasma cytokine responses (IFN-c, IL-2,
IL-4, IL-5 and IL-13) other than IL-10 (Blish et al., 2010). Those
patients were recruited in a randomised clinical trial on albenda-
zole treatment during HIV infection without TB, where there was
a signiﬁcant increase in mean CD4+ T cell counts at follow-up in
the sub-group of patients infected with Ascaris compared with
the placebo group (+109 CD4+ cells/mm3), and a trend for lower
HIV-1 RNA levels (Kaur et al., 2002; Turner et al., 2008). In the cur-
rent study, we similarly observed a non-signiﬁcant increase in
CD4+ T cells but primarily among the HIV-negative TB patients.
In the sub-group analysis for Ascaris infection there was no effect
of deworming in any of the primary or secondary outcomes,
although the small sample size compromised this analysis (data
not shown).
We believe this is the ﬁrst controlled clinical trial on effects of
deworming in TB patients including immunological readouts but
we acknowledge that it has limitations. The most important one
is that the study is not adequately powered to rule out a clinical
effect of albendazole treatment. In that regard, it should be noted
that the sub-group analyses should be interpreted with caution.
A low enrolment rate and lack of resources to continue the study
for more than 3 years limited recruitment. In the immunological
analyses, the skewed distribution of the HIV co-infected patients
as well as the absence of stimulation with helminth antigens limit
the possibility to make ﬁrm conclusions about effects on the host
response against TB. The optimal time to follow up immunologicalchanges after deworming is not known and 12 weeks may have
been too early, which in turn could have underestimated potential
differences. Nevertheless, we still detected signiﬁcant changes in
eosinophilia and levels of IL-10 at the 12 week evaluation.
In conclusion, albendazole treatment did not affect the clinical
outcome of helminth co-infected TB patients as evaluated by the
TB score after 2 months. Deworming of helminth co-infected TB
patients was effective and induced a signiﬁcant decline in periph-
eral eosinophils and IL-10. The reduction in IL-10 observed with
albendazole treatment in this study has a potential impact on the
course of TB since IL-10 is a potent immunomodulatory cytokine
that suppresses the induction of a speciﬁc, Th1-directed immune
response to TB. Larger multi-centre studies are warranted to fur-
ther investigate the clinical and immunological effects of dewor-
ming on the outcome of pulmonary TB.Acknowledgements
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